Panitumumab

Generic name: Panitumumab
Brand names: Vectibix
Dosage form: intravenous solution (20 mg/mL)
Drug class: EGFR inhibitors

Usage of Panitumumab

Panitumumab is used to treat a certain type of metastatic colorectal cancer that has progressed after treatment with other chemotherapy.

Panitumumab is used only if your tumor is a wild-type RAS tumor, for which your doctor will test.

Panitumumab may also be used for purposes not listed in this medication guide.

Panitumumab side effects

Get emergency medical help if you have signs of an allergic Reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during the injection. Tell your caregiver right away if you feel dizzy, nauseated, light-headed, chilled, feverish, or have chest tightness or trouble breathing.

Seek emergency medical attention at the first sign of any skin rash. Panitumumab may cause severe skin problems that can lead to widespread infection and possibly death.

Panitumumab may cause serious side effects. Call your doctor at once if you have:

severe or ongoing diarrhea;

sudden chest pain or discomfort, wheezing, dry cough or hack, feeling short of breath;

redness, swelling, or irritation of your eyes or eyelids, vision changes;

swelling in your face;

low potassium level--leg cramps, constipation, irregular heartbeats, fluttering in your chest, increased thirst or urination, numbness or tingling, muscle weakness or limp feeling;

dehydration symptoms--feeling very thirsty or hot, being unable to urinate, heavy sweating, or hot and dry skin;

signs of a kidney problem--little or no urinating; painful or difficult urination; swelling in your feet or ankles; feeling tired or short of breath; or

skin problems--severe or worsening acne, swelling or infection around your fingernails or toenails, skin itching, redness, dryness, peeling, cracking, or oozing.

Your cancer treatments may be delayed or permanently discontinued if you have certain side effects.

Common side effects of panitumumab may include:

acne, dry skin, rash, itching;

swelling or irritation around your fingernails or toenails;

loss of appetite, nausea, diarrhea;

blisters or ulcers in your mouth, red or swollen gums, trouble swallowing;

tired feeling, weakness; or

low potassium.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Panitumumab

You should not use panitumumab if you are allergic to it.

Tell your doctor if you have ever had:

lung disease, breathing problems;

an ulcer on the cornea of your eye (keratitis); or

an electrolyte imbalance (such as low levels of calcium, magnesium, or potassium in your blood).

Panitumumab may harm an unborn baby. Use effective birth control to prevent pregnancy while you are using panitumumab, and for at least 2 months after your last dose. Tell your doctor if you become pregnant.

You may have irregular menstrual periods while receiving panitumumab.

You should not breastfeed while using panitumumab.

Relate drugs

How to use Panitumumab

Usual Adult Dose for Colorectal Cancer:

6 mg/kg IV over 60 minutes every 14 days; if the first infusion is tolerated, administer subsequent infusions over 30 to 60 minutes; administer doses higher than 1000 mg over 90 minutesComments:¬¬-Prior to initiation of therapy, assess RAS mUTAtional status in colorectal tumors and cOnfirm the absence of a RAS mutation in exon 2 (codons 12 and 13), exon 3 (codons 59 and 61), and exon 4 (codons 117 and 146) of both KRAS and NRAS. -See Dose Adjustments for dosage modifications in patients experiencing infusion reactions or dermatologic toxicity.Uses: For the treatment of wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer (mCRC): -In combination with FOLFOX for first-line treatment. -As monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.

Warnings

Panitumumab may cause severe skin problems that can lead to widespread infection and possibly death. Seek emergency medical attention at the first sign of any skin rash.

What other drugs will affect Panitumumab

Other drugs may affect panitumumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all your current medicines and any medicine you start or stop using.

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.